The National Institutes of Health issued two new funding opportunity announcements late last month for projects focused on the impact of cellular, molecular, and genomic technologies on cancer care and non-viral gene transfer systems, both of which specifically name RNA interference as a research avenue.
The NIH also reissued an FOA for grants focused on Alzheimer's disease drug discovery, which also cites RNAi as a key area of research.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
